Histone Deacetylase Inhibitor Valproic Acid Suppresses the Growth and Increases the Androgen Responsiveness of Prostate Cancer Cells

Overview

Journal Cancer Lett

Specialty Oncology

Date 2011 Aug 25

PMID 21862211

Citations 18

Authors

Yu-Wei Chou

Nagendra K Chaturvedi

Shougiang Ouyang

Fen-Fen Lin

Dharam Kaushik

Jue Wang

Isaac Kim

Ming-Fong Lin

Affiliations

Soon will be listed here.

Abstract

We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their potential prostate cancer (PCa) therapy. Upon HDAC inhibitors-treatment, LNCaP cell growth was suppressed, correlating with increased cellular prostatic acid phosphatase (cPAcP) expression, an authentic protein tyrosine phosphatase. In those cells, ErbB-2 was dephosphorylated, histone H3/H4 acetylation and methylation increased and cyclin proteins decreased. In PAcP shRNA-transfected C-81 cells, valproic acid (VPA) efficacy of growth suppression was diminished. Further, VPA pre-treatment enhanced androgen responsiveness of C-81, C4-2 and MDA PCa2b-AI cells. Thus, cPAcP expression is involved in growth suppression by HDAC inhibitors in PCa cells, and VPA pre-treatments increase androgen responsiveness.

Citing Articles

From HDAC to Voltage-Gated Ion Channels: What's Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer.

Pellegrino M, Ricci E, Ceraldi R, Nigro A, Bonofiglio D, Lanzino M Cancers (Basel). 2022; 14(18).

PMID: 36139561 PMC: 9497059. DOI: 10.3390/cancers14184401.

From Therapy Resistance to Targeted Therapies in Prostate Cancer.

Moreira-Silva F, Henrique R, Jeronimo C Front Oncol. 2022; 12:877379.

PMID: 35686097 PMC: 9170957. DOI: 10.3389/fonc.2022.877379.

Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells.

Duarte D, Rema A, Amorim I, Vale N Biomolecules. 2022; 12(2).

PMID: 35204691 PMC: 8961626. DOI: 10.3390/biom12020190.

Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs.

Duarte D, Cardoso A, Vale N Int J Mol Sci. 2021; 22(14).

PMID: 34299028 PMC: 8306770. DOI: 10.3390/ijms22147408.

New drugs are not enough‑drug repositioning in oncology: An update.

Armando R, Mengual Gomez D, Gomez D Int J Oncol. 2020; 56(3):651-684.

PMID: 32124955 PMC: 7010222. DOI: 10.3892/ijo.2020.4966.

References

Chuang T, Chen S, Lin F, Veeramani S, Kumar S, Batra S . Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J Biol Chem. 2010; 285(31):23598-606. PMC: 2911278. DOI: 10.1074/jbc.M109.098301. View

Hunter T, Cooper J . Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell. 1981; 24(3):741-52. DOI: 10.1016/0092-8674(81)90100-8. View

Zylka M, Sowa N, Taylor-Blake B, Twomey M, Herrala A, Voikar V . Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron. 2008; 60(1):111-22. PMC: 2629077. DOI: 10.1016/j.neuron.2008.08.024. View

Lin M, Clinton G . Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity. Biochem J. 1986; 235(2):351-7. PMC: 1146694. DOI: 10.1042/bj2350351. View

Hirsch C, Bonham K . Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett. 2004; 570(1-3):37-40. DOI: 10.1016/j.febslet.2004.06.018. View

Veeramani S, Yuan T, Chen S, Lin F, Petersen J, Shaheduzzaman S . Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer. 2005; 12(4):805-22. DOI: 10.1677/erc.1.00950. View

Zelivianski S, Igawa T, Lim S, Taylor R, Lin M . Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter. Oncogene. 2002; 21(23):3696-705. DOI: 10.1038/sj.onc.1205471. View

Lin M, Lee M, Zhou X, Andressen J, Meng T, Johansson S . Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J Urol. 2001; 166(5):1943-50. View

Vihko P . Human prostatic acid phosphatases: purification of a minor enzyme and comparisons of the enzymes. Invest Urol. 1979; 16(5):349-52. View

10.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

11.

Lin M, Meng T, Rao P, Chang C, Schonthal A, Lin F . Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem. 1998; 273(10):5939-47. DOI: 10.1074/jbc.273.10.5939. View

12.

Igawa T, Lin F, Lee M, Karan D, Batra S, Lin M . Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate. 2002; 50(4):222-35. DOI: 10.1002/pros.10054. View

13.

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

14.

Lin M . Effect of cell density on androgen regulation of the mRNA level of human prostatic acid phosphatase. Mol Cell Endocrinol. 1994; 99(2):R21-4. DOI: 10.1016/0303-7207(94)90025-6. View

15.

Wedel S, Sparatore A, Soldato P, Al-Batran S, Atmaca A, Juengel E . New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J Cell Mol Med. 2008; 12(6A):2457-66. PMC: 4514123. DOI: 10.1111/j.1582-4934.2008.00271.x. View

16.

Veeramani S, Igawa T, Yuan T, Lin F, Lee M, Lin J . Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene. 2005; 24(48):7203-12. DOI: 10.1038/sj.onc.1208852. View

17.

Abbas A, Gupta S . The role of histone deacetylases in prostate cancer. Epigenetics. 2008; 3(6):300-9. PMC: 2683066. DOI: 10.4161/epi.3.6.7273. View

18.

Chen S, Karan D, Johansson S, Lin F, Zeckser J, Singh A . Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate. 2007; 67(5):557-71. DOI: 10.1002/pros.20551. View

19.

Reif A, Schlesinger R, FISH C, Robinson C . Acid phosphatase isozymes in cancer of the prostate. Cancer. 1973; 31(3):689-99. DOI: 10.1002/1097-0142(197303)31:3<689::aid-cncr2820310331>3.0.co;2-f. View

20.

Lin M, Xia X, Biela B, Lin F . The cellular level of prostatic acid phosphatase and the growth of human prostate carcinoma cells. Differentiation. 1994; 57(2):143-9. DOI: 10.1046/j.1432-0436.1994.5720143.x. View